Meeting
2023 ASCO Annual Meeting
Efficacy of function-enhanced, re-activatable, dual-specific CAR T cells pre-loaded with oncolytic virus for immunotherapy of high-grade glioma.
Authors
Mason Webb
Mayo Clinic, Rochester, MN
Mason Webb , Jason Tonne , Jill Thompson , Jose Pulido , Matthew C. Coffey , Houra Loghmani , Kevin Joseph Harrington , Hardev S. Pandha , Alan Melcher , Rosa Maria Diaz , Ian F. Parney , Richard Vile
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2062)
DOI
10.1200/JCO.2023.41.16_suppl.2062
Abstract #
2062
Poster Bd #
419
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Effect of the killing style of individual CAR T cells on the clinicopathological behavior of therapeutic products in the clinic.
First Author: Ahmed Z Gad
Poster
2018 ASCO Annual Meeting
A phase I trial of T4 CAR T-cell immunotherapy in head and neck squamous cancer (HNSCC).
First Author: Sophie Papa
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Targeting CD19-negative relapsed B-acute lymphoblastic leukemia using trivalent CAR T cells.
First Author: Kristen Fousek
Poster
2017 ASCO Annual Meeting
Chimeric antigen receptor (CAR) T cells genetically engineered to deliver IL-12 to the tumor microenvironment in ovarian cancer.
First Author: Oladapo O. Yeku